#USA #Fort Lauderdale #Washington University #Kefunova #SKNV

SKNV Secures Exclusive Rights to Innovative Skin Treatment

In a significant advancement in dermatological treatment, SKNV, a prominent name in dermatologic innovation, has officially acquired exclusive commercialization rights for a unique patent portfolio developed by Washington University in St. Louis. This patent covers a novel combination therapy that utilizes Fluorouracil and Calcipotriene, aimed at effectively addressing skin conditions motivated by sun damage, chiefly Actinic Keratosis (AK), a well-known precursor to more dangerous skin cancers like squamous cell carcinoma (SCC).

Understanding the Combination Therapy

The patented formulation is already available on the market under the brand name Kefunova™ Cream (containing 5% Fluorouracil and 0.005% Calcipotriene). This cream represents a cutting-edge solution for a myriad of dermatological issues caused by prolonged sun exposure. SKNV is committed to producing this combination in its Fort Lauderdale facility, recognized by the FDA, ensuring adherence to the highest quality standards and effective medication consistency.

Clinical Significance and Expert Insights

“Field-directed therapy offers a most efficient approach for treating Widespread actinic damage in keratinocytes,” commented Dr. Lynn A. Cornelius, one of the leading dermatology experts at Washington University. While traditional methods may focus solely on visible lesions, this innovative therapy aims to target subclinical AKs that may not yet be apparent, addressing the underlying factors contributing to skin cancer risk.

Clinical trials led by prominent dermatologists, including Dr. Shawn Demehri from Massachusetts General Hospital, have shown promising results. One of the key findings highlights that the combination therapy could significantly reduce AK lesions in just four days, compared to standard treatments that could take weeks. These insights are invaluable, given that AK affects approximately 40 million individuals annually in the United States alone.

Broad Implications for Patients

The ramifications of this new therapy are profound. With the ever-growing prevalence of AK and the potential progression to SCC, SKNV's innovative cream offers not only a faster treatment option but also enhances patient convenience and compliance. Patients suffering from AK can look forward to a treatment option that is more aligned with contemporary dermatological practices.

Moreover, recent guidelines from the American Academy of Dermatology emphasize the importance of managing not just the visible signs but taking preventive measures against potential malignancies arising from untreated AKs.

Dr. Malkin, founder and CEO of SKNV, expressed his commitment to continuing the development of pivotal dermatologic therapies that meet the current needs of both patients and healthcare providers. He asserted that the strong clinical interest in Kefunova reflects its potential to transform patient care vastly.

Moving Forward

Moving forward, SKNV plans to leverage its partnership with Washington University to expand accessibility and awareness of this innovative treatment. By making Kefunova widely available, they hope to redefine the standard of care in dermatology, targeting both visible and hidden aspects of skin cancer.

In conclusion, as dermatology continues to evolve, innovations like Kefunova place patients at the forefront of care, ensuring that they have access to state-of-the-art treatments designed to improve their health outcomes against Actinic Keratosis and related conditions.

For further information about the product and its benefits, visit SKNV's official site.